Rabbi Samuel Herzfeld’s hand was disinfected by Dr. Chao Wang on Monday, July 27, 2020, during a clinical trial for the coronavirus vaccine at Meridian Clinical Research in Maryland.
Amanda Andred-Rvedes | W. Washington Post | Getty Images
A top group advising U.S. health officials predicted on Tuesday that four late-stage coronavirus vaccine tests backed by the United States would fail to yield positive results.
The National Academies of Science, Engineering and Medicine has released a draft report stating that if U.S. The federal plan for the distribution of the coronavirus vaccine is indicated if and when it is approved for public use. The vaccine will be shared in four phases with health care workers and vulnerable Americans, such as the elderly and people with underlying health conditions, it comes first.
The group said it expects all volunteers participating in U.S. vaccine testing to receive an approved vaccination as soon as possible, regardless of its phased guidelines, as “doing so is a typical standard of the vaccine trial protocol.” It said the Trump administration’s pace of Operation Operation War is expected to support three trials of seven to 30,000 people and assumes four of them will fail.
The group wrote in the draft report that “four tests will fail, and all subjects in those tests are vaccinated.” “Three trials will be successful, and 15,000 participants of each test assigned to the placebo position, under the ratio of 1: 1 between members of the treatment group compared to the placebo group, are vaccinated and approved.”
According to a study published in the Scientific Journal of Biostatistics, the success rate for infectious disease vaccines to be developed through clinical trials and to obtain regular approval is 43.34%.
According to the Centers for Disease Control and Prevention, in phase three testing, the vaccine is usually given to thousands of people and tested for efficacy and safety.
The U.S. has invested billions of dollars in six potential vaccines over the past month, as part of the pace of Operation Operation Line, including drug companies Pfizer, Moderna and AstraZeneca, which have entered all three phases.
Some vaccine candidates are being made before regulatory approval. Due to the epidemic, U.S. health officials are accelerating the development of vaccine candidates, investing in several phases of research, however, nothing can happen if the vaccine does not remain effective or safe.
U.S. health officials say they are hopeful they will find at least one safe and effective vaccine by the end of the year and possibly more than one by early 2021.
Scientists say there is no guarantee that scientists will get a safe and effective vaccine. They warn that questions remain about how the human body reacts after being infected with the virus.
For example, scientists expect that antibodies provide a small amount of protection against getting Covid-19, but they could not say for sure because the coronavirus was discovered about eight months ago.
Researchers in Hong Kong reported last month that the first confirmed case of Covid-19 re-infection appeared to be in a man who was first infected with the virus in late March and then, 48 months later, became infected again.
.
